This cohort study assesses the occurrence of late adverse events for adult patients with aggressive large B-cell non-Hodgkin lymphoma treated with commercially available CD19-targeted chimeric antigen receptor (CAR) T cells. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.